3-HO-PCP Powder per 0.5 gram

per 0.5 gram 25,00

Pay your order with Bitcoin or other Crypto Currency and get 15% discount: 23,75 (-1,25)

3-HO-PCP (or 3-Hydroxyphencyclidine) was first synthesized in 1978 to investigate the structure-activity relationship of phencyclidine (PCP) derivatives. It was further explored alongside PCP in the 1980s, where it was discovered to possess μ-opioid agonist activity in animal models.

Its potential as a research chemical for human use was not suggested until 1999, when a chemist using the pseudonym John Q. Beagle reported on its significantly increased potency relative to PCP, as well as its “profoundly enhanced affinity for the opiate receptor” which was estimated to give it analgesic activity one order of magnitude lower than morphine.

Availability: In stock

Discount # of items Discount %
2% 5 - 10 2%
5% 11 - 20 5%
10% 20 - 50 10%
15% 51 - 100 15%
20% 101 + 20%
BULK DISCOUNT: Order More, Pay Less!
X 0.5 grams

3-HO-PCP (or 3-Hydroxyphencyclidine) was first synthesized in 1978 to investigate the structure-activity relationship of phencyclidine (PCP) derivatives. It was further explored alongside PCP in the 1980s, where it was discovered to possess μ-opioid agonist activity in animal models.

Its potential as a research chemical for human use was not suggested until 1999, when a chemist using the pseudonym John Q. Beagle reported on its significantly increased potency relative to PCP, as well as its “profoundly enhanced affinity for the opiate receptor” which was estimated to give it analgesic activity one order of magnitude lower than morphine.

3-HO-PCP
3-HO-PCP

On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the “harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)”, although the act does not classify drugs from harm. The report suggests that all analogs of MXE should also become class B drugs, and proposed a catch-all clause covering both existing and unresearched arylcyclohexylamines, including 3-HO-PCP.

3-HO-PCP, or 3-hydroxyphencyclidine, is a synthetic dissociative of the arylcyclohexylamine class. The structure of 3-HO-PCP consists of cyclohexane, a six-member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring, a nitrogenous six member band, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R3 with a hydroxy group.

3-HO-PCP is a structural analog of PCP and a homolog 3-MeO-PCP.

Like other arylcyclohexylamine dissociatives, 3-HO-PCP acts principally as an NMDA receptor antagonist.

The NMDA (N-Methyl-D-Aspartate) receptor, a specific subtype of the glutamate receptor, modulates the transmission of electrical signals between neurons within the brain and spinal cord; for the signals to pass, the receptor must be open. Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity causes network disintegration, some research suggests, by hyper-connectivity throughout the brain. This causes an increase in noise (random, nonsensical and erroneous data) on the cerebral network, and thus produces loss of normal cognitive and affective processing, psychomotor functioning, anesthesia. This is often observed in those showing psychosis or induced with high-dose IV THC or Ketamine in healthy participants. Please check references.

Unlike many other dissociatives, 3-HO-PCP has also been found to have appreciable affinity as a μ-opioid receptor agonist in animal models. However, how far this applies to humans remains unknown.

Appearance

Powder

CAS Number

79787-43-2

Common name(s)

3-(1-Piperidin-1-ylcyclohexyl)phenol, 3-HO-PCP, 3-Hydroxyphencyclidine, Hydroxyphencyclidine

InChi Key

AMSXTZUCNOKUEN-UHFFFAOYSA-N

IUPAC name

3-[1-(Piperidin-1-yl)cyclohexyl]phenol

Price is per

0.5 grams

Psychoactive class

Dissociative, Opiod, Sedative

SMILES

c1cc(cc(c1)O)C2(CCCCC2)N3CCCCC3

Shopping Cart
Hey, wait!Stay update and be notified when we are back

Hi!

Subscribe to our newsletter to receive an update when these issues are fixed!